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Introduction. Acute kidney injury (AKI) is common in the intensive care unit (ICU) and associated with poor outcome. Plasma
B-type natriuretic peptide (BNP) is a biomarker related to myocardial overload, and is elevated in some ICU patients. There is a
high prevalence of both cardiac and renal dysfunction in ICU patients. Aims. To investigate whether plasma BNP levels in the ﬁrst
48hourswereassociatedwithAKI inICUpatients.Methods.Westudied acohortof34consecutiveICU patients.Primaryoutcome
was presence of AKI on presentation, or during ICU stay. Results. For patients with AKI on presentation, BNP was statistically
higher at 24 and 48 hours than No-AKI patients (865 versus 148pg/mL; 1380 versus 131pg/mL). For patients developing AKI
during 48 hours, BNP was statistically higher at 0, 24 and 48 hours than No-AKI patients (510 versus 197pg/mL; 552 versus
124pg/mL; 949 versus 104pg/mL). Conclusion. Critically ill patients with AKI on presentation or during ICU stay have higher
levels of the cardiac biomarker BNP relative to No-AKI patients. Elevated levels of plasma BNP may help identify patients with
elevated risk of AKI in the ICU setting. The mechanism for this cardiorenal connection requires further investigation.
1.Introduction
Acute kidney injury (AKI) is a common clinical problem
in intensive care unit (ICU) patients and independently
predicts poor outcome [1–4]. In the ICU setting, the overall
incidenceofAKIisapproximately36%[5,6],andanincreas-
ingtrendhasbeenreported[7,8].Cardiacdysfunction isalso
common in patients with AKI in the ICU, and increasing
interest exists in how the interaction of these two systems
aﬀects clinical outcomes in this group of patients.
B-type or brain natriuretic peptide (BNP) is a neuro-
hormone secreted from ventricular myocardium in response
to myocardial stretching and volume overload [9]. BNP
has diagnostic and prognostic utility in patients with
acute decompensated heart failure [10–13], and BNP is an
independent predictor for cardiovascular events and overall
mortality in various patient groups including those with
chronic kidney disease [14–20].
However, it remains unclear whether plasma levels of
BNP are useful in predicting AKI in critically ill patients.
Therefore, ourstudyaimed toinvestigate whether BNPlevels
in the ﬁrst 48 hours may be useful in diagnosis of established
AKI.
2.Methods
2.1. Patients and Study Protocol. We studied a cohort of 34
consecutive patients admitted to the ICU of “San Bortolo”
Hospital, Vicenza, Italy, between December 2007 and April2 International Journal of Nephrology
2008.Patientsrequiringmechanicalventilationandadmitted
on any day from Monday to Wednesday were included, and
we excluded patients with acute coronary syndrome or acute
myocardial infarction. The study was approved by the Insti-
tutional Review Board. The primary outcome was presence
ofAKI during admission ordevelopmentofAKI during ICU
stay. Patients were classiﬁed as having AKI if any time during
the ﬁrst 48 hours after enrollment they had
(1) an increment of serum creatinine (SCr) of 0.3mg/dL
or more or an increase of at least 50% from baseline
and/or,
(2) an episode of urine output less than 0.5mL/kg/hr for
more than six hoursdespiteﬂuidchallenge of500mL
or more.
AKI was classiﬁed according to the RIFLE (Risk, Injury, Fail-
ure, Loss, and End-stage kidney disease) criteria [21]. The
Sequential Organ Failure Assessment (SOFA) scores were
calculated using standard methods [22]. Blood samples for
plasma BNP and renal function were taken within 6 hours
fromadmission and24and48hourslater,toinvestigateasso-
ciation of BNP levels with clinical and laboratory parameters
and SOFA score.
2.2.BNPMeasurement. Plasma samples for BNPwere stored
at minus 80 degrees Celsius. Plasma BNP was measured with
ﬂuorescence-based immunoassay with the Triage point-of-
care analyzer (Biosite Inc., San Diego, Calif., USA), which is
a rapid quantitative measurement of BNP concentration in
EDTA-anticoagulated whole blood or plasma. The method
used single-use plastic cartridge with immobilized BNP
antigen and BNP-speciﬁc monoclonal antibodies conjugated
to ﬂuorescent nanoparticles.
2.3. Statistical Analysis. Categorical variables are expressed
as percentage and were compared with Fisher’s Exact Test.
Normally or near normally distributed variables were pre-
sented as means ± standard deviations (SD); non-normally
distributed continuous data were presented as medians
and interquartile ranges (IQR). Diﬀerences between groups
were analyzed using Student’s t and Mann-Whitney tests as
appropriate.Diﬀerencesbetween repeated measures within a
group were analyzed using Friedman test. Statistical analysis
was performed using the SPSS 15.0 (SPSS Inc, Chicago, Ill,
USA). A P value <. 05 was considered signiﬁcant.
3.Results
During the study, a total of 34 patients were admitted to
the ICU, and, of these, 26 met the inclusion criteria and
had suﬃcient data for analysis. Furthermore, 9 (34.6%)
fulﬁlled criteria for AKI, 5 (19.2%) had AKI on admission,
and 4 (15.4%) more developed AKI during 48 hours.
Characteristics of the patients are shown in Tables 1 and 2.
Given the diﬀerences between SCr, age, and BNP at baseline,
we did examine for correlations between these variables.
WhilebaselineSCrandBNPwerenotsigniﬁcantlycorrelated
(r = 0.27, P = .19), there was a weak correlation between
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Figure 1:The ROC-AUC forBNP related to the presence ofAKI on
admission or development of AKI during ICU stay is 0.830.
age and SCr (r = 0.39, P = .048) and a stronger correlation
between age and baseline BNP (r = .46, P = .02).
In patients with AKI on admission, we found a higher
SOFA score (10.0 ± 2.4v e r s u s6 .1 ± 2.1; P = .002) and,
as expected, higher SCr levels (1.85, IQR 1.76-1.94, versus
0.82, IQR 0.69-1.00mg/dL; P = .001) compared to no-
AKI patients. Moreover, AKI patients tended to have higher
BNP values on admission compared to no-AKI patients
(510, IQR 370–544, versus 197, IQR 57–393pg/mL; P =
.06) (Table 1). Plasma BNP levels were also statistically
signiﬁcantly higher for AKI patients at 24 and 48 hours
after admission compared to no-AKI patients (Table 3). In
addition, the increase in BNP of AKI patients during 48
hours (from 510 to 1380pg/mL) was signiﬁcant (P = .012)
(Table 3 and Figure 2).
An additional 4 patients developed AKI after admission.
These patients had on admission higher SCr (1.14 versus
0.82mg/dL) and BNP (338 versus 197pg/mL) levels com-
pared to no-AKI patients.
We also analyzed levels of SCr and BNP in all patients
developing AKI at any point during 48 hours (n = 9). For
these patients, the diﬀerence in BNP versus no-AKI patients
at admission was even more pronounced (510, IQR 232–
832, versus 197, IQR 36–353pg/mL; P = .038). Also, for
the 9 patients developing AKI at any time during ICU stay,
SCr and BNP levels at baseline and at 24 and 48 hours were
signiﬁcantly higher compared to no-AKI patients (Table 4).
4.Discussion
Alargeproportionofpatientsadmittedtohospital,especially
in the critical care setting, have various degrees of heart
and kidney dysfunction [23]. Primary disorders of one ofInternational Journal of Nephrology 3
Table 1: Characteristics of AKI and no-AKI patients at ICU admission.
All
(26)
AKI
(5)
No-AKI
(21) P value
Male 57.7% 60.0% 57.1% .91
Age, years 59.7 ±21.77 7 .6 ±7.35 5 .4 ±21.9 .037
Weight, kg 77.4 ±13.47 4 .5 ±8.87 8 .1 ±14.3. 3 6
SOFA score 6.9 ±2.71 0 .0 ±2.46 .1 ±2.1 .002
Serum creatinine,
mg/dL∗
0.89
(0.64 to 1.28)
1.85
(1.76 to 1.94)
0.82
(0.69 to 1.00) .001
Plasma BNP,
pg/mL∗
228
(67.5 to 544)
510
(370 to 544)
197
(57 to 393) .06
Diagnosis on ICU
admission
Trauma 30.8% 0% 38.1% .28
Pulmonary 26.9% 60% 19.0% .10
Neurologic 26.9% 0% 33.3% .28
Other 15.4% 40.0% 9.5% .16
AKI: Acute kidney injury.
I C U :I n t e n s i v ec a r eu n i t .
SOFA: Sequentialorgan failure assessment.
BNP: B-type or brain natriuretic peptide.
∗median and interquartile range.
Table 2: Median of creatinine and BNP of all patients during 48 hours.
Baseline 24 hours 48 hours P value
Serum creatinine, mg/dL 0.89
(0.64 to 1.28)
0.86
(0.65 to 1.50)
0.80
(0.71 to 0.89) .86
Plasma BNP, pg/mL 228
(67.5 to 544)
282.5
(55.1 to 474)
220
(78.4 to 565) .92
BNP: B-type or brain natriuretic peptide.
Table 3: Median of creatinine and BNP during 48 hours of ICU stay for patients with or without AKI on admissionto ICU. The increase in
BNP of AKI patients is signiﬁcant (P = .012).
AKI
(5)
No-AKI
(21) P value
Serum creatinine, mg/dL
Baseline 1.85
(1.70 to 3.85)
0.82
(0.68 to 1.01) .001
24 hours 2.49
(1.60 to 4.53)
0.79
(0.64 to 0.97) .001
48 hours 2.14
(1.47 to 5.24)
0.78
(0.63 to 0.89) .004
Plasma BNP, pg/mL
Baseline 510
(369 to 690)
197
(42 to 485) .06
24 hours 865
(344 to 948)
148
(47 to 447) .047
48 hours 1380
(985 to 1625)
131
(43 to 297) <.001
BNP: B-type or brain natriuretic peptide.
I C U :I n t e n s i v ec a r eu n i t .
AKI: Acute kidney injury.4 International Journal of Nephrology
Table 4: Median of creatinine and BNP during 48 hours for patients developing AKI or not any time during their ICU stay.
AKI
(9)
No-AKI
(17) P value
Serum creatinine, mg/dL
Baseline 1.76
(1.01 to 1.90)
0.81
(0.68 to 0.89) .002
24 hours 1.70
(1.07 to 2.53)
0.70
(0.63 to 0.89) .001
48 hours 1.56
(0.98 to 2.47)
0.74
(0.62 to 0.82) .001
Plasma BNP, pg/mL
Baseline 510
(232 to 832)
197
(36 to 353) .038
24 hours 552
(344 to 948)
124
(47 to 407) .019
48 hours 949
(297 to 1435)
104
(29 to 236) .002
BNP: B-type or brain natriuretic peptide.
AKI: Acute kidney injury.
I C U :I n t e n s i v ec a r eu n i t .
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Figure 2: Increase in median of BNP of patients with AKI on
admissionto ICU (P = .012).
these two organs often result in secondary dysfunction or
injurytotheother[24].Suchpathophysiologicalinteractions
represent the basis for a clinical entity often referred to
as the cardiorenal syndrome (CRS) [25]. Limited data are
available regarding the diagnostic and prognostic utility of
BNP in patients with AKI in intensive care unit. In a recent
study, Park et al. [26] demonstrated that BNP levels have
the diagnostic and prognostic capability for CRS type 4 in
ICU patients, according to the novel classiﬁcation of CRS
[27, 28]. In our study, BNP was able to predict the presence
of AKI on admission or development of AKI during ICU
stay with a ROC-AUC 0.830 (Figure 1). No previous studies
have focused onthe signiﬁcance of BNPin patientswith AKI
admitted to the ICU.
In ICU setting, emerging cardiac and renal impairment
are strongly connected on neurohormonal basis via renin-
angiotensin-aldosterone system BNP and nitric oxide, the
sympathetic nervous system and other pathways such as
coagulation and inﬂammation.
Burchilletal. haveshown in experimental animal models
that the acute eﬀects of AKI on the heart occur as early as
few hours after kidney injury, and that changes in cardiac
structure are associated with increased cardiac BNP [29].
It could also be speculated that the changes in BNP
observed in our study may partly reﬂect the pathophysiology
between kidney and heart in AKI, the so-called CRS type
3 or acute renocardiac syndrome. In this category, AKI is
believed to be the primary inciting factor, and cardiac failure
is a common and in often times a fatal complication of AKI
[27].
In our study, we demonstrate a dynamic interaction
between AKI and plasma BNP levels in a cohort of mechan-
ically ventilated ICU patients who were admitted primarily
for noncardiac diagnosis. This calls attention to the possible
utility of this marker in detecting AKI. Further, the results
support the need for additional study of the potential value
of plasma BNPlevels in discrimination between AKIand no-
AKI in critically ill patients.
T oo u rk n o w l e d g e ,t h i si st h eﬁ r s ti n v e s t i g a t i o no ft h e
association between plasma BNP levels and AKI in critically
ill patients. We acknowledge some limitations in this study.
Extensive information regarding patient comorbidities was
not available and could not be added to our analysis. Plasma
BNP levels can be aﬀected by other variables such as age,
and in our study AKI patients were signiﬁcantly older than
no-AKI patients, and age was correlated with baseline BNP,
hence some of the association between BNP and AKI may
have reﬂected the risk of AKI related to age. Additionally,
while patients with acute myocardial infarction and acute
coronary syndromes were excluded, massive information
about previous or current cardiac dysfunction was not
collected and could have inﬂuenced plasma BNP levels.International Journal of Nephrology 5
Furthermore, we did not perform objective assessment of
cardiac function to document that increased BNP in this
setting would be due to myocardial dysfunction. Finally, this
study was not designed to look at the prognostic value of
plasma BNP levels in critically ill patients with AKI.We hope
that these preliminary results will encourage further study of
these important questions.
5.Conclusion
In this pilot study, we havedemonstrated forthe ﬁrst time an
association between plasma BNP levels and AKI in critically
ill patients. Patients with AKI have higher levels of BNP
comparedtono-AKIpatients,andinAKIpatientsBNPlevels
continue to increase during the subsequent 48 hours. Our
results suggest that plasma BNP may distinguish the occur-
renceofAKI.Additionalstudiesare necessary toconﬁrmour
ﬁndings and to further shed light on the pathophysiologic
interaction between kidney and heart during AKI.
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